MWM
RPRX icon

Maridea Wealth Management’s Royalty Pharma RPRX Stock Holding History

Maridea Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,492
Closed -$604K – 447
2025
Q3 		$604K Buy
+16,492
New +$597K 0.09% 207

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maridea Wealth Management's RPRX Position: Q4 2025 in Review

Maridea Wealth Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 16,492 shares — an estimated $604K sold.

Maridea Wealth Management first reported a position in RPRX in Q3 2025 and held it in 1 quarter. The position peaked at $604K in Q3 2025. 538 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Maridea Wealth Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Maridea Wealth Management sold 16,492 Royalty Pharma shares in Q4 2025, an estimated $604K.
  • Maridea Wealth Management first reported a position in Royalty Pharma in Q3 2025 and held it in 1 quarter.
  • Maridea Wealth Management's Royalty Pharma position peaked at $604K in Q3 2025.
  • 538 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Maridea Wealth Management's 13F filing for Q4 2025, filed 8 Jan 2026.